Children and young adults born completely deaf because of mutations in the OTOF gene have gained measurable hearing after receiving a single injection of gene therapy into the inner ear, with improvements appearing in as few as four to six weeks. Across multiple clinical trials conducted in China and the United States, participants ranging from infants under one year old to adults in their early thirties have shown gains in auditory brainstem response thresholds and, in some cases, speech perception. The results, drawn from several independent trial programs using different viral vectors, represent the largest and longest body of evidence yet for a one-time molecular treatment for inherited deafness.
Why restoring hearing with a single cochlear injection matters right now
OTOF mutations cause a condition called DFNB9, a form of autosomal recessive deafness in which the cochlea’s hair cells are structurally intact but cannot transmit sound signals because they lack the protein otoferlin. That distinction is central to why gene therapy works here: the target tissue is preserved, so delivering a functional copy of the gene can restore the missing protein without rebuilding damaged anatomy. As investigators affiliated with the research explained through Harvard-based reporting, the cochlear injection is followed by a waiting period of roughly four to six weeks before the first signs of hearing improvement emerge.
One hypothesis gaining traction among researchers is that baseline distortion-product otoacoustic emissions, or DPOAEs, may be the strongest independent predictor of how well a patient responds at around six weeks, outperforming factors like age or the specific OTOF variant once dose and vector type are held constant. The largest published dataset, covering 42 participants aged approximately 0.8 to 32.3 years with up to 2.5 years of follow-up, includes analysis of baseline DPOAEs and variant type as predictors of response. If confirmed across trials, this biomarker could help clinicians identify which patients are most likely to benefit and how quickly, sharpening candidate selection before surgery.
Trial data from three independent programs using AAV vectors
The clinical evidence comes from at least three distinct gene therapy programs, each using adeno-associated virus (AAV) vectors but with different capsid designs and delivery strategies. The convergence of positive results across these programs strengthens the case that the approach itself, not just a single product, can work.
The broadest dataset comes from a multicentre trial of an AAV1 vector carrying human OTOF that enrolled 42 participants across multiple sites. Ages ranged from approximately 0.8 to 32.3 years, and the therapy was delivered via a single cochlear injection through the round window. Follow-up extending to 2.5 years showed sustained benefit, with the trial also examining which patient characteristics predicted stronger responses. An earlier single-arm trial using the same AAV1 construct, reported in a peer‑reviewed study indexed on PubMed, documented auditory brainstem response improvements by 26 weeks at specified dose levels, along with speech-perception gains in treated children.
A separate single-arm trial used a different capsid, Anc80L65, to deliver AAV-OTOF via a single round-window injection. According to a Nature Medicine report, that study enrolled 10 participants aged 1.5 to 23.9 years across five sites in China, with audiometric outcomes tracked over time. Participants showed clinically meaningful shifts in pure-tone thresholds in the treated ear, and several achieved levels compatible with understanding spoken language in quiet environments. Importantly, the safety profile in this cohort-monitored through standard otologic exams, imaging and laboratory tests-was broadly consistent with other inner-ear AAV trials, with no reports of systemic serious adverse events directly attributed to the vector.
The third program, DB-OTO, takes a dual AAV1 approach delivered by intracochlear infusion as a single administration. A peer-reviewed report in the New England Journal of Medicine described prespecified endpoints at week 24, including the proportion of participants meeting a pure-tone average of 70 dB HL or better and ABR threshold targets. Early participants, including very young children, demonstrated rapid shifts from profound deafness toward the severe or moderate range, with some beginning to detect environmental sounds and speech-like stimuli. Updates from the CHORD trial of DB-OTO, presented at a recent gene and cell therapy meeting, described initial hearing improvements appearing around six weeks in one child, consistent with the time course observed in the other OTOF programs.
Durability, re-dosing, and gaps in the published record
The most pressing open question is how long the therapeutic effect lasts. The 2.5-year follow-up window from the largest AAV1-OTOF cohort is encouraging but still short relative to a patient’s lifetime. To date, no primary source in the published record details long-term immunogenicity assays beyond that timeframe, leaving uncertainty about whether the viral vector or the expressed protein will trigger immune responses that erode hearing gains over years or decades. Because cochlear hair cells are largely non-dividing, the expectation is that transgene expression could be long-lived, but that assumption has not yet been fully tested in humans.
Researchers have already begun exploring what happens when a second dose is needed. A single-arm trial described in another Nature Medicine article examined outcomes and safety after a repeat dose of AAV-mediated gene therapy for OTOF-related deafness. That re-administration study explicitly builds on earlier single-dose work and addresses immunologic considerations that arise when a patient’s immune system has already encountered the viral vector. Participants were monitored for neutralizing antibodies, inflammatory markers and changes in hearing function after the second exposure.
The existence of this re-dosing research creates a tension with the headline promise of a “one-and-done” cure. If immunity to the capsid or transgene limits the effectiveness or safety of a second administration, clinicians may face difficult decisions about when in a child’s life to deliver the initial treatment. Administering gene therapy early may maximize developmental benefits for language and cognition, but it could also mean that any waning effect later in life is harder to address. Conversely, delaying treatment could preserve the option of re-dosing but at the cost of critical early years of auditory experience.
Another gap in the record is how these therapies perform across the full spectrum of OTOF variants and clinical presentations. Most published participants have classic DFNB9 with preserved cochlear structure and absent or severely impaired ABR responses. Less is known about patients with atypical mutations, partial residual hearing or coexisting inner-ear abnormalities. The early evidence suggests that baseline DPOAEs and structural integrity of the cochlea may matter more than the precise genotype, but larger, more diverse cohorts will be needed to confirm that assumption and to refine eligibility criteria.
What comes next for OTOF gene therapy
The convergence of outcomes across three independent AAV programs has transformed OTOF-related deafness from a purely supportive-care condition into one with a plausible molecular intervention. For families, the prospect of a single surgery that can move a child from profound silence to meaningful sound perception within months is profound. For clinicians and regulators, however, the work is only beginning. Longer-term follow-up will have to clarify durability, late-onset safety signals and the feasibility of re-dosing. Comparative studies may be needed to determine whether one vector design or delivery route offers superior benefit–risk balance.
As more children are treated, the field will also have to grapple with practical questions: how to screen newborns for OTOF mutations, how to counsel parents about timing and expectations, and how to integrate gene therapy with or in place of cochlear implants. For now, the emerging data show that restoring hearing through a single cochlear injection is no longer a theoretical goal but a demonstrated possibility-one that will require careful, long-term stewardship to realize its full potential over a patient’s lifetime.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
